Clinical Research Directory
Browse clinical research sites, groups, and studies.
Tislelizumab Combined With Chemotherapy and Relayed Radiotherapy in First-line Treatment of ES-SCLC
Sponsor: Anhui Provincial Cancer Hospital
Summary
To explore the efficacy and safety of Tislelizumab combined with chemotherapy and relayed radiotherapy in the first-line treatment of extensive small cell lung cancer
Official title: Efficacy and Safety of Tislelizumab Combined With Chemotherapy and Relayed Radiotherapy in the First-line Treatment of Extensive Small Cell Lung Cancer: a Prospective, Multicenter, Phase II Clinical Study
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
56
Start Date
2025-02-25
Completion Date
2028-04-01
Last Updated
2025-09-24
Healthy Volunteers
No
Interventions
Tislelizumab, Carboplatin /Cisplatin, Etoposide
Induction therapy stage LDRT: lung lesions, 15Gy/5f; Maintenance therapy phase SBRT: The main residual lesions evaluated by the investigators, 30Gy/5f;
Locations (1)
Anhui Cancer Hospital
Hefei, Anhui, China